You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥(02142.HK)治療腫瘤藥物臨床試驗 結果抗腫瘤活性良好
阿思達克 04-17 09:41
和鉑醫藥(02142.HK)公布,獨立開發的porustobart(HBM4003)聯用特瑞普利單抗治療晚期高級別神經內分泌腫瘤患者的Ib期臨床試驗結果(試驗代碼:NCT05167071,「Ib期研究」)已計劃於今年美國癌症研究協會(AACR)年會的海報會議上發表,並在AACR的線上會議上發布。結果顯示,藥物於晚期高級別神經內分泌腫瘤患者中顯示出良好的抗腫瘤活性及可接受的安全性。 該等結果顯示了porustobart作為腫瘤免疫基石療法的巨大潛力。公司亦正在進行其他晚期實體腫瘤(如肝細胞癌及黑色素瘤)的聯用治療臨床研究。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account